Publicacions en col·laboració amb investigadors/ores de Hospital de Gran Canaria Dr. Negrin (11)

2024

  1. Real-world persistence of initial targeted therapy strategy in monotherapy versus combination therapy in patients with chronic inflammatory arthritis

    European Journal of Clinical Investigation, Vol. 54, Núm. 2

2023

  1. Correction: Factors associated with discontinuation of biologics in patients with inflammatory arthritis in remission: data from the BIOBADASER registry (Arthritis Research & Therapy, (2023), 25, 1, (86), 10.1186/s13075-023-03045-3)

    Arthritis Research and Therapy

  2. Factors associated with discontinuation of biologics in patients with inflammatory arthritis in remission: data from the BIOBADASER registry

    Arthritis Research and Therapy, Vol. 25, Núm. 1

  3. Long-term retention of golimumab treatment in clinical practice in a large cohort of patients with rheumatoid arthritis, axial spondyloarthritis and psoriatic arthritis

    Musculoskeletal Care, Vol. 21, Núm. 1, pp. 189-197

2022

  1. Correction to: Real-World Effectiveness and Treatment Retention of Secukinumab in Patients with Psoriatic Arthritis and Axial Spondyloarthritis: A Descriptive Observational Analysis of the Spanish BIOBADASER Registry (Rheumatology and Therapy, (2022), 9, 4, (1031-1047), 10.1007/s40744-022-00446-9)

    Rheumatology and Therapy

  2. Real-World Effectiveness and Treatment Retention of Secukinumab in Patients with Psoriatic Arthritis and Axial Spondyloarthritis: A Descriptive Observational Analysis of the Spanish BIOBADASER Registry

    Rheumatology and Therapy, Vol. 9, Núm. 4, pp. 1031-1047

  3. SER-SEPAR recommendations for the management of rheumatoid arthritis-related interstitial lung disease. Part 1: Epidemiology, risk factors and prognosis

    Reumatologia Clinica, Vol. 18, Núm. 8, pp. 443-452

  4. SER-SEPAR recommendations for the the management of rheumatoid arthritis-related interstitial lung disease. Part 2: Treatment

    Reumatologia Clinica, Vol. 18, Núm. 9, pp. 501-512

2021

  1. Role of targeted therapies in rheumatic patients on COVID-19 outcomes: Results from the COVIDSER study

    RMD Open, Vol. 7, Núm. 3

2016

  1. Cut-offs and response criteria for the Hospital Universitario la Princesa Index (HUPI) and their comparison to widely-used indices of disease activity in rheumatoid arthritis

    PLoS ONE, Vol. 11, Núm. 9

2014

  1. Índices compuestos para evaluar la actividad de la enfermedad y el daño estructural en pacientes con lupus eritematoso: Revisión sistemática de la literatura

    Reumatologia Clinica